Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ZBH - Zimmer Biomet Holdings, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$92.86
DETAILS
HIGH:
$105.00
LOW:
$83.00
MEDIAN:
$92.00
CONSENSUS:
$92.86
UPSIDE:
1.80%
Stock News
D.A. Davidson & CO. Has $2.67 Million Stake in Zimmer Biomet Holdings, Inc. $ZBH
D.A. Davidson and CO. boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE: ZBH) by 170.3% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,520 shares of the medical equipment provider's stock after acquiring an additional 18,597 shares during the
Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
WARSAW, Ind., July 14, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Chintan Desai has been named president of the company's Asia Pacific Region, effective immediately.
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
WARSAW, Ind., July 13, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its second quarter earnings conference call will be webcast on Wednesday, August 5, 2026 at 8:30 a.m.
Is Zimmer Biomet Stock the Right Pick for Your Portfolio Now?
Zimmer Biomet ZBH appears well positioned for growth in the coming quarters, supported by the continued execution of its market strategies centered on People and Culture, Operational Excellence, and Innovation and Diversification pillars. Growth in the knee business revenues is backed by the robust adoption of its cementless offerings.
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Medical device maker Zimmer Biomet to hire 500 in 3 years for tech centre in India
Medical device maker Zimmer Biomet plans to hire 500 employees over the next three years for its newly opened technology centre in Bengaluru, a senior executive said, as the U.S.-listed company expands its presence in India.
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal
PCRX is set to sell its iovera franchise to ZBH in a deal worth up to $140M as it sharpens focus on biopharmaceutical growth.
ISRG vs. ZBH: Which Robotic Surgery Stock Offers Better Upside Now?
ISRG stands out over ZBH as stronger revenue growth, rising procedure demand, and expanding AI-driven innovation support better upside in 2026.
Why Zimmer Biomet (ZBH) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zimmer Biomet: Does Slow And Steady Still Win The Race?
Zimmer Biomet Holdings trades at a steep valuation discount despite strong free cash flow and high margins. ZBH's entrenched position in orthopedic implants, robust cash generation, and loyal installed base underpin reliable earnings. Recent results show net sales up 9.3%, adjusted EPS up 15.5%, and adjusted gross margin rising to 73.0%.
Zimmer Biomet Holdings, Inc. (ZBH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Zimmer Biomet Holdings, Inc. (ZBH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
/PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet
Zimmer (ZBH) Up 3.1% Since Last Earnings Report: Can It Continue?
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026
WARSAW, Ind., May 22, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2026.
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?
Abbott vs. Zimmer Biomet: surgical equipment stocks face diverging growth, acquisitions, and valuation shifts as investors weigh momentum and margins.
Zimmer Biomet Holdings, Inc. (ZBH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Zimmer Biomet Holdings, Inc. (ZBH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Zimmer Biomet Increases Share Repurchase Expectations -- Up to $1 Billion by Year End
WARSAW, Ind., May 12, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it now anticipates repurchasing up to $1 billion of its common stock during fiscal year 2026, a $250 million increase from the company's prior assumption.
Price Targets
Zimmer Biomet initiated with a Market Perform at BMO Capital
$95.00
(was $87.56)
BMO Capital
Zimmer Biomet price target lowered to $92 from $98 at Truist
$92.00
(was $80.80)
Truist Financial
Zimmer Biomet price target lowered to $83 from $93 at Canaccord
$83.00
(was $82.80)
Canaccord Genuity
Zimmer Biomet price target lowered to $105 from $110 at Stifel
$105.00
(was $82.80)
Rick Wise
·
Stifel Nicolaus
Zimmer Biomet price target lowered to $92 from $100 at Baird
$92.00
(was $82.80)
Robert W. Baird
Zimmer Biomet price target lowered to $94 from $100 at Barclays
$94.00
(was $82.80)
Matt Miksic
·
Barclays
Zimmer Biomet price target lowered to $100 from $104 at Barclays
$100.00
(was $96.69)
Matt Miksic
·
Barclays
Zimmer Biomet price target raised to $89 from $86 at UBS
$89.00
(was $93.69)
UBS
Zimmer Biomet price target lowered to $86 from $88 at UBS
$86.00
(was $85.27)
UBS
Zimmer Biomet price target raised to $99 from $97 at Bernstein
$99.00
(was $94.08)
Bernstein
Zimmer Biomet downgraded to Sell from Neutral at Goldman Sachs
$93.00
(was $94.08)
David Roman
·
Goldman Sachs
Zimmer Biomet upgraded to Outperform from In Line at Evercore ISI
$120.00
(was $90.02)
Evercore ISI
Zimmer Biomet downgraded to Neutral from Outperform at Baird
$100.00
(was $92.52)
Jeff Johnson
·
Robert W. Baird
Zimmer Biomet price target lowered to $110 from $118 at Stifel
$110.00
(was $87.91)
Rick Wise
·
Stifel Nicolaus
Zimmer Biomet price target lowered to $112 from $122 at BTIG
$112.00
(was $88.05)
Johnson Rice
Zimmer Biomet price target lowered to $105 from $112 at Barclays
$105.00
(was $103.18)
Barclays
Zimmer Biomet price target raised to $122 from $118 at BTIG
$122.00
(was $94.71)
Ryan Zimmerman
·
BTIG
Zimmer Biomet price target lowered to $111 from $115 at RBC Capital
$111.00
(was $95.53)
RBC Capital
Zimmer Biomet price target raised to $118 from $115 at Stifel
$118.00
(was $100.36)
Stifel Nicolaus
Zimmer Biomet initiated with a Buy at Rothschild & Co Redburn
$130.00
(was $100.21)
Ed Ridley-Day
·
Redburn Partners